Cardiff University has an excellent track record of commercially exploiting the outcomes of its research. Forming a company to exploit University know-how or expertise is one of the routes available, and is managed through a close working relationship with Fusion IP. Licensing and royalty agreements, which enable businesses to use Cardiff research commercially, bring enormous benefits to a range of companies. Examples of recent highlights and successes are shown below along with current opportunities. If you are interested in obtaining further information please contact us.
Cardiff University’s innovative sports rehabilitation technology ‘Vector’ has successfully secured a further £45K investment from Cardiff Partnership Fund. This investment is to provide software which will accompany the three demo kits for placements with Sports Clubs over the summer close season.
OpenIQE working with IPCoP on CoInnovate Conference
Following the success of the Academia-Industry Innovation Camp in March 2015, IPCoP again worked with OpenIQE to highlight Welsh innovation at a national level. OpenIQE’s two-day CoInnovate brought together UK academia, industry and investors for an open innovation conference, as well as a series of engaging workshops and multinational speakers. The conference was held in the Mercure Cardiff on the 23rd and 24th June 2015.
Drug Developed at Cardiff has great potential for Cancer Therapy
The potential impact of a new cancer drug invented in Cardiff has been called 'remarkable' at the world's biggest gathering of oncologists. Designed to stop patients becoming resistant to common therapies, tests have shown Acelarin to be effective in tackling a range of different cancers. The treatment was invented in laboratories at Cardiff University. Professor Chris McGuigan from the University's School of Pharmacy described a decade's work on the new drug in a BBC news item
New anti-cancer stem cell compound in development
Lightning strikes twice for the anti-cancer drug developers in Cardiff University’s European Cancer Stem Cell Research Institute. Cardiff University scientists have developed a novel anti-cancer stem cell agent capable of targeting aggressive tumour forming cells originating from the breast, pancreas, colon and prostate. The new 0H14 compound has been licensed by Tiziana Life Sciences, a British-based pharmaceutical company. It will now undergo further development before proceeding to clinical trials. Tests have shown it to be effective in eliminating a number of different kinds of cancers cells, including cancer stem cells from human breast cancer patient biopsies.
Novel semiochemicals prepared through synthetic biology for crop protection
A successful collaboration between the School of Chemistry at Cardiff University and the Chemical Ecology Group at Rothamsted Research, which combines Cardiff’s expertise in Synthetic/Chemical Biology and Rothamsted’s expertise in the exploitation of semiochemicals for crop protection, has led to a significant breakthrough in the rational design of novel olfactory ligands, with promising commercial applications in crop protection against insect pests. These research outcomes are currently generating media interest (e.g. interviews on Radio 4’s Farming Today and the AAAS radio station , as well as an article in Chemistry World ). The collaborators, who already have an excellent track record in leveraging BBSRC responsive mode funding, recently applied for follow-on funding to further their research as a commercial opportunity. Indeed, given the growing need to reduce agricultural reliance on pesticides and the rise of insecticide resistance, the technology has significant market potential as a tool for integrated pest management (IPM).
New KTP Sponsor joins existing funders
Innovate UK, The Department for Culture, Media & Sport (DCMS) are jointly investing up to £0.5m to help UK companies establish new Knowledge Transfer Partnerships (KTPs) in the area of cyber security. This funding will be allocated on a rolling basis until the funding is committed. The funding is predominantly at supporting collaborations between HEIs and SMEs. The UK cyber security sector is currently worth over £6billion and employs over 40,000 people.
Could smell hold the key to ending pesticide use?
Scientists from the School of Chemistry and Rothamsted Research have, for the first time, created tiny molecules which mirror a natural occurring smell known to repel insects. The team hope that their research could provide a new way of designing and developing small smell molecules which would be otherwise be too difficult to produce by usual scientific and commercial methods.
IPCoP meets with more key companies
One of the aims of the IP Collaboration Project is to engage with key companies in key sectors, to promote easier access to university IP. IPCoP is pleased to be meeting with Tata and the Welsh Opto-Electronics Forum to explore new opportunities. The collaboration have previously met with Dwr Cymru Welsh Water, General Dynamics and IQE, amongst others.
High hopes for potential new asthma therapeutic
Cardiff scientists have identified the potential root cause of asthma and an existing drug that offers a new treatment. Published in April’s Science Translational Medicine journal, University researchers, working in collaboration with scientists at King's College London and the Mayo Clinic describe the previously unproven role of the calcium sensing receptor (CaSR) in causing asthma, a disease which affects 300 million people worldwide. Professor Riccardi and her collaborators are now seeking funding to determine the efficacy of calcilytic drugs in treating asthmas that are especially difficult to treat, particularly steroid-resistant and influenza-exacerbated asthma, and to test these drugs in patients with asthma.
Partnership with Tiziana Pharmaceuticals to support work on a novel anti-cancer agent
Share issue conditionally raises £20m for Fusion IP, who have agreed deals to work with Swansea University and the University of Nottingham
MedaPhor group plc, a company spun out of research at Cardiff University, has today floated on the AIM market of the London Stock Exchange
Positive progress for Diurnal's CATCH (Chronocort® As Treatment for Congenital Adrenal Hyperplasia) clinical study
Fault Current Limited (“FCL”), has been awarded a £635,000 grant from the Department of Energy and Climate Change (DECC)
Exclusive distribution agreement with Tellyes Scientific Inc (“Tellyes”) to sell MedaPhor’s range of ultrasound simulators into mainland China
'First-In-Man' Trials Success for Ultravision™ Technology